At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 265 enrolled
Drug / intervention
Memantine +1 moredrug
Likely dose
Memantine 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy of Memantine on Functional Communication in Patients With Alzheimer's Disease (AD)
In Brief
A Phase 4 clinical trial evaluating Memantine and placebo for Alzheimer's Disease. Completed, enrolled 265 participants across 25 sites in 3 countries.
Detailed Summary
The objective of this study is to evaluate the effect of memantine versus placebo on functional communication in patients with Alzheimer's Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesAustralia, New Zealand, South Africa
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2007
First PostedMay 2007
Primary CompletionNov 2008
TodayJul 2026
First PostedMay 4, 2007
Enrollment StartApr 1, 2007
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.2 years ago
Interventions
Memantinedrug
Memantine 20mg (10mg twice daily) oral administration for 12 weeks
placebodrug
Placebo oral administration twice daily for 12 weeks